Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.
台灣2型糖尿病患者中虛弱對GLP-1受體激動劑與SGLT2抑制劑效果及安全性的影響:一項回顧性全國性縱向研究。
Lancet Healthy Longev 2024-09-16
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy.
GLP-1 受體激動劑與 SGLT2 抑制劑在 2 型糖尿病中的作用:多重心代謝效應及聯合療法的附加價值。
Drugs 2024-09-28
Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis.
GLP-1 受體激動劑與 SGLT-2 抑制劑聯合使用於老年 2 型糖尿病患者的療效與安全性:一項 meta-analysis。
Am J Transl Res 2024-12-16
The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required.
在糖尿病虛弱老年人中使用 SGLT-2 抑制劑和 GLP-1RA:需要個性化的方案。
Metabolites 2025-01-24
The use of SGLT2 inhibitors and GLP-1 receptor agonists in older patients: a debate on approaches in CKD and non-CKD populations.
在老年患者中使用 SGLT2 抑制劑和 GLP-1 受體激動劑:在 CKD 和非 CKD 人群中的方法辯論。
Clin Kidney J 2025-02-05
Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DM.
第二線降血糖藥物在年長第二型糖尿病患者中的相對安全性:來自LEGEND-T2DM的多國真實世界證據
medRxiv 2025-05-19